Quick adjustment of imaging tracer payload, for in vivo applications of theranostic nanostructures in the brain

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 4, 2014, Pages 851-858

  Agulla, Jesús ^a,b   Brea, David ^a,c   Argibay, Bárbara ^a   Novo, Mercedes ^d   Campos, Francisco ^a   Sobrino, Tomás ^a   Blanco, Miguel ^a   Castillo, José ^a   Ramos Cabrer, Pedro ^a  

^a University Hospital of Santiago de Compostela   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c FUNDACIÓ INSTITUT D INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL   (Spain)

^d UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Contrast quenching; Gadolinium chelates; Molecular imaging; Probe payload; Theranostics

Indexed keywords

LIPOSOMES; MAGNETIC RESONANCE IMAGING; MOLECULAR IMAGING; MOLECULES;

BLOOD-BRAIN BARRIER; BRAIN MRI; GADOLINIUM CHELATES; IMAGING PROBE; QUICK ADJUSTMENT; RODENT MODELS; THERANOSTIC AGENTS; THERANOSTICS;

GADOLINIUM;

GADOLINIUM; GADOLINIUM CHELATE; GADOTERATE MEGLUMINE; LIPOSOME; NANOMATERIAL; CONTRAST MEDIUM; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN; CONTROLLED STUDY; IN VIVO STUDY; MACROMOLECULE; MALE; MOLECULE; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; RAT; SENSIBILITY; SENSITIVITY ANALYSIS; ANIMAL; CHEMISTRY; PROCEDURES; RADIOGRAPHY; SPRAGUE DAWLEY RAT;

ANIMALS; BRAIN; CONTRAST MEDIA; GADOLINIUM; LIPOSOMES; MAGNETIC RESONANCE IMAGING; MALE; NANOPARTICLES; RATS, SPRAGUE-DAWLEY;

EID: 84900327772     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.12.004     Document Type: Article

References (35)

1. Picard F.J., Bergeron M.G. Rapid molecular theranostics in infectious diseases. Drug Discov Today 2002, 7(21):1092-1101.
2. Fernandez-Fernandez A., Manchanda R., McGoron A. Theranostic Applications of Nanomaterials in Cancer: Drug Delivery, Image-Guided Therapy, and Multifunctional Platforms. Appl Biochem Biotechnol 2011, 165(7):1628-1651.
3. Lobatto M.E., Fuster V., Fayad Z.A., Mulder W.J.M. Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat Rev Drug Discov 2011, 10(11):835-852.
4. Shim M.S., Kwon Y.J. Stimuli-responsive polymers and nanomaterials for gene delivery and imaging applications. Adv Drug Deliv Rev 2012, 64(11):1046-1059.
5. Kinlay S. Changes in Stroke Epidemiology, Prevention, and Treatment. Circulation 2011, 124(19):e494-e496.
6. Allen T.M. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sci 1994, 15(7):215-220.
7. Drummond D.C., Meyer O., Hong K., Kirpotin D.B., Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999, 51(4):691-743.
8. Kabanov A.V. Polymer genomics: an insight into pharmacology and toxicology of nanomedicines. Adv Drug Deliv Rev 2006, 58(15):1597-1621.
9. Kataoka K., Harada A., Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev 2001, 47(1):113-131.
10. Lee C.C., MacKay J.A., Frechet J.M., Szoka F.C. Designing dendrimers for biological applications. Nat Biotechnol 2005, 23(12):1517-1526.
11. Lu Y., Low P.S. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev 2002, 54(5):675-693.
12. Nori A., Kopecek J. Intracellular targeting of polymer-bound drugs for cancer chemotherapy. Adv Drug Deliv Rev 2005, 57(4):609-636.
13. Widera A., Norouziyan F., Shen W.C. Mechanisms of TfR-mediated transcytosis and sorting in epithelial cells and applications toward drug delivery. Adv Drug Deliv Rev 2003, 55(11):1439-1466.
14. Denora N., Trapani A., Laquintana V., Lopedota A., Trapani G. Recent advances in medicinal chemistry and pharmaceutical technology-strategies for drug delivery to the brain. Curr Top Med Chem 2009, 9(2):182-196.
15. Vlieghe P., Khrestchatisky M. Medicinal Chemistry Based Approaches and Nanotechnology-Based Systems to Improve CNS Drug Targeting and Delivery. Med Res Rev 2013, 33(3):457-516.
16. Mulder W.J., Griffioen A.W., Strijkers G.J., Cormode D.P., Nicolay K., Fayad Z.A. Magnetic and fluorescent nanoparticles for multimodality imaging. Nanomedicine (Lond) 2007, 2(3):307-324.
17. Mulder W.J., Strijkers G.J., van Tilborg G.A., Griffioen A.W., Nicolay K. Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging. NMR Biomed 2006, 19(1):142-164.
18. Caravan P. Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chem Soc Rev 2006, 35(6):512-523.
19. Ghaghada K., Hawley C., Kawaji K., Annapragada A., Mukundan S. T1 relaxivity of core-encapsulated gadolinium liposomal contrast agents-effect of liposome size and internal gadolinium concentration. Acad Radiol 2008, 15(10):1259-1263.
20. Hak S., Sanders H.M., Agrawal P., Langereis S., Grull H., Keizer H.M., et al. A high relaxivity Gd(III)DOTA-DSPE-based liposomal contrast agent for magnetic resonance imaging. Eur J Pharm Biopharm 2009, 72(2):397-404.
21. Ramos-Cabrer P., Agulla J., Argibay B., Perez-Mato M., Castillo J. Serial MRI study of the enhanced therapeutic effects of liposome-encapsulated citicoline in cerebral ischemia. Int J Pharm 2011, 405(1-2):228-233.
22. Rouser G., Fkeischer S., Yamamoto A. Two dimensional then layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids 1970, 5(5):494-496.
23. Haacke E.M., Brown R.W., Thompson M.R., Venkatesan R. Magnetic resonance imaging: physical principles and sequence design. New York 1999, J. Wiley & Sons, New York; CHichester.
24. Jover A., Meijide F., Mosquera V., Tato J.V. A step-by-step dilution-extraction method for laboratory experiments. J Chem Educ 1990, 67(6):530.
25. Langereis S., Geelen T., Grull H., Strijkers G.J., Nicolay K. Paramagnetic liposomes for molecular MRI and MRI-guided drug delivery. NMR Biomed 2013, 26(7):728-744.
26. Bulte J.W., de Cuyper M., Despres D., Frank J.A. Short- vs. long-circulating magnetoliposomes as bone marrow-seeking MR contrast agents. J Magn Reson Imaging 1999, 9(2):329-335.
27. Aragnol D., Leserman L.D. Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo. Proc Natl Acad Sci U S A 1986, 83(8):2699-2703.
28. Gabizon A., Papahadjopoulos D. The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim Biophys Acta 1992, 1103(1):94-100.
29. Torchilin V.P., Omelyanenko V.G., Papisov M.I., Bogdanov A.A., Trubetskoy V.S., Herron J.N., et al. Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. Biochim Biophys Acta 1994, 1195(1):11-20.
30. Li S.D., Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 2008, 5(4):496-504.
31. Ramos-Cabrer P., Campos F. Liposomes and nanotechnology in drug development: focus on neurological targets. Int J Nanomed 2013, 8(1):951-960.
32. Strijkers G.J., Mulder W.J., van Heeswijk R.B., Frederik P.M., Bomans P., Magusin P.C., et al. Relaxivity of liposomal paramagnetic MRI contrast agents. MAGMA 2005, 18(4):186-192.
33. Laurent S., Elst L.V., Thirifays C., Muller R.N. Paramagnetic liposomes: inner versus outer membrane relaxivity of DPPC liposomes incorporating lipophilic gadolinium complexes. Langmuir 2008, 24(8):4347-4351.
34. Laurent S., Vander Elst L., Thirifays C., Muller R.N. Relaxivities of paramagnetic liposomes: on the importance of the chain type and the length of the amphiphilic complex. Eur Biophys J 2008, 37(6):1007-1014.
35. Courant T., Roullin V.G., Cadiou C., Callewaert M., Andry M.C., Portefaix C., et al. Hydrogels incorporating GdDOTA: towards highly efficient dual T1/T2 MRI contrast agents. Angew Chem 2012, 51(36):9119-9122.